Skip to main content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

12-09-2017 | Breast cancer | ESMO 2017 | News

First-line abemaciclib supported for HR+HER2– advanced breast cancer

Results from the MONARCH 3 study give support to first-line use of the oral selective CDK4/6 inhibitor abemaciclib, taken alongside nonsteroidal aromatase inhibitor therapy, in patients with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

26-07-2017 | Non-small cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Here, Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

08-08-2017 | Non-small cell lung cancer | Article

At a glance: The KEYNOTE lung cancer trials

Overwhelmed by the sheer number of KEYNOTE trials? Cannot keep them straight in your head? Here is our quick guide to the KEYNOTE lung cancer trials.

Latest from across the site

21-09-2017 | FDA | Drug approval | News


Bevacizumab biosimilar approved in USA

More details about this decision are just a click away

21-09-2017 | Neuroendocrine tumors | Article

Early recurrence of neuroendocrine liver metastasis after curative hepatectomy: risk factors, prognosis, and treatment

The objective of this retrospective study was to investigate the risk factors, treatment, and prognosis of early recurrence of neuroendocrine tumor liver metastasis (NELM) after hepatic resection.

Zhang XF, Beal EW, Chakedis J et al. J Gastrointest Surg. 2017.

20-09-2017 | ESMO 2017 | Video

ESMO 2017: Melanoma highlights

ESMO Melanoma Faculty Coordinator Olivier Michielin discusses the CheckMate 238, COMBI-AD, and BRIM8 trials presented at the third Presidential symposium.

20-09-2017 | Epidemiology | ESMO 2017 | News

ESMO 2017 in brief

Cancer vigilance may be warranted for stroke survivors

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

20-09-2017 | FDA | News


Copanlisib, low-dose cabazitaxel receive FDA go ahead

Click through to read more on these approvals

20-09-2017 | Colorectal cancer | Article

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis

The aim of this meta-analysis was to gain insight into the optimal sequence and combination for the use of anti-epidermal growth factor receptor therapy in colorectal cancer. 

van Helden EJ et al. Cancer Metastasis Rev. 2017; 36: 395. doi:10.1007/s10555-017-9668-y

Meet our Advisory Board

image credits